This is the authors' abstract. We don't add key points for this paper.
Malignant mesothelioma remains a difficult proposition in the clinic, with few accurate molecular markers available to guide diagnosis and patient management, and a dearth of effective treatments. Recent evidence implicates microRNAs-short non-coding RNAs involved in post-transcriptional regulation of gene expression-in mesothelioma biology. Emerging evidence suggests that exploring aberrant microRNA expression will not only improve our understanding of the disease, but will also lead to the identification of new molecular biomarkers and therapeutic targets.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Glen Reid (2015) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: